Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection

Partnership expands access to breakthrough blood-based cancer screening into
Superpower's comprehensive health check and personalized plans.

SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, the first all-in-one proactive health platform, announced a strategic partnership with GRAIL, Inc. (Nasdaq: GRAL) to bring members access to the Galleri^® multi-cancer early detection (MCED) test. Timed with the start of National Cancer Prevention and Early Detection Month, the partnership reflects a shared belief that cancer detection must evolve to meet a changing reality — removing traditional barriers to advanced testing and putting earlier insight, data, and control directly in people's hands.

Cancer is changing — screening has to change with it

Cancer remains the second leading cause of death in the United States, with an estimated 40% of Americans expected to be diagnosed in their lifetime. It is a disease defined not by a single risk factor, but by biology, exposure, and time, often developing silently long before symptoms appear.

At the same time, cancer patterns are shifting. Early-onset cancers (diagnosed before age 50) have increased nearly 80% globally since 1990, with projections suggesting continued growth in the years ahead. This shift has underscored a broader reality: cancer often begins long before it is clinically detected, yet our screening systems have largely remained unchanged.

The early detection gap

Today's cancer screening standards address only a fraction of the problem. Recommended screening exists for just five cancer types, and as a result, nearly 86% of cancers are not caught by standard screening tests such as mammograms, colonoscopies, and PSA tests. Most cancers are still detected only after symptoms appear, often after disease has progressed.

With a disease this prevalent, the question is unavoidable: Why hasn't detection caught up?

"We treat red lights, not yellow ones," said Prabhat Dhar, EVP Enterprise at Superpower. "The healthcare system only reacts once conditions become diagnoses, claims, and long-term costs. Our partnership with GRAIL represents a fundamental shift, giving people the ability to screen for cancer signals before symptoms appear, when intervention can be most effective, while pairing it with Superpower's broader capabilities for a more comprehensive approach."

Expanding the early warning system

Through this partnership, Superpower members nationwide will have access to the Galleri test, a first-of-its-kind, clinically validated blood test that can detect a signal shared by more than 50 cancer types, including many of the deadliest cancers that lack recommended screening. The test also predicts the cancer signal origin, helping guide efficient diagnostic workup.

Recent data from GRAIL's PATHFINDER 2 study — the largest U.S. multi-cancer early detection interventional study to date — demonstrated that adding Galleri to standard recommended screenings increased cancer detection more than seven-fold. More than half of cancers detected were at stage I or II, when treatment outcomes are typically better.

Beyond the test: integrated health intelligence

Unlike standalone screening services, Superpower integrates the Galleri test into its preventative health platform. Members receive not just test results, but contextual interpretation alongside their 100+ biomarker panel, AI-powered insights, and access to care teams.

"A test result without context creates anxiety, not action," said Max Marchione, Superpower's Chief Executive Officer. "Our platform connects cancer screening data with the full picture of someone's biomarker health so members and their care teams can make informed decisions together."

Implications for employers and benefits leaders

For employers, the partnership addresses a critical gap in population health management. Cancer diagnoses often appear suddenly in claims data, long after the window for early intervention and screening has closed. By offering multi-cancer early detection alongside comprehensive biomarker testing, employers gain visibility into emerging risks before they become high-cost events.

Superpower's enterprise offering positions the Galleri test within a broader early warning system — identifying health risk signals that traditional benefits programs miss.

A new standard for proactive care

"We're witnessing the beginning of a transformative era for cancer screening," said Josh Ofman, MD, MSHS, President of GRAIL. "Superpower's integrated approach combining comprehensive biomarker testing with multi-cancer early detection represents the future of proactive health management. Together, we're working to make early detection accessible to more people, when cancer may be more treatable."

Availability

The Galleri test is available as an add-on through the Superpower platform. The test requires a prescription, is recommended for adults with an elevated risk for cancer such as those aged 50 or older, and should be used in addition to recommended single-cancer screening tests. Members can complete the blood draw through Quest Diagnostics' nationwide network of approximately 3,000+ patient access points and at home or at the office. 

About Superpower

Superpower is your home for health that combines comprehensive biomarker testing (100+ markers), AI-powered insights, and clinical care teams to help people understand and optimize their health. Superpower members receive personalized action plans that evolve with their biology, supported by 24/7 access to an AI health companion, human clinical team and marketplace for more. For further information, visit www.superpower.com.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning to detect and identify multiple deadly cancer types in earlier stages. The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique "fingerprint" of cancer. The Galleri test has not been cleared or approved by the Food and Drug Administration. For more information, visit www.grail.com.

Important Safety Information: The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. The Galleri test has not been cleared or approved by the Food and Drug Administration.

SOURCE Superpower